Analysis of prognostic factors of patients with malignant peritoneal mesothelioma

Abstract

Background: The study aims to find out independent prognostic factors for patients with malignant peritoneal mesothelioma (MPeM).

Methods: Patients with pathologically proven MPeM were retrospectively reviewed. Potential prognostic factors were analyzed, including age, gender, asbestos exposure, body mass index (BMI), treatment, and laboratory results, such as blood routine examination and liver functions. The influences of various risk factors on the prognoses were analyzed by univariate analysis. A Cox regression model analysis established independent factors for the survival prognosis of the patients.

Results: Seventy MPeM patients, including 33 patients who received intraperitoneal chemotherapy with cisplatin, 14 patients who received systemic chemotherapy with cisplatin + pemetrexed, and 21 untreated patients were included in this study. The 1-year survival was 32.9%, the 2-year survival was 10%, and the 3-year survival was 2.9%. The median age of MPeM was 62 years, and the female-to-male ratio was 1:0.56. The univariate and multivariate analyses showed that treatment, albumin (ALB), and blood neutrophil-to-lymphocyte ratio (NLR) were independent factors that affected the overall survival (OS) of MPeM patients.

Conclusion: High blood NLR and hypoalbuminemia are adverse prognostic factors for MPeM patients. Systemic chemotherapy and intraperitoneal chemotherapy can prolong the survival period.

Keywords: Albumin; Malignant peritoneal mesothelioma; NLR; Prognostic factors; Treatment.

Fig. 1

a The survival function of the original lifetime data. b Kaplan–Meier survival curves depicting OS according to the ALB. The OS rate of patients with ALB < 35 g/l was significantly lower than that of patients with ALB ≥ 35 g/l (P = 0.018). c Kaplan–Meier survival curves depicting OS according to the NLR. The OS rate of patients with a NLR < 3 was significantly higher than that of patients with a NLR ≥ 3 (P = 0.012). d Kaplan–Meier survival curves depicting OS according to the treatment. The OS rate of untreated patients was significantly lower than that of treated patients (P = 0.000). There was no significant difference between the patients receiving intraperitoneal chemotherapy with cisplatin and the patients receiving systemic chemotherapy with cisplatin + pemetrexed (P > 0.05)